Asacol

What is it?

Composition

Asacol contains mesalazine, an aminosalicylate with a local anti-inflammatory effect in the intestinal mucosa. The tablets are designed to release the active substance in the colon, where it helps reduce inflammation, abdominal discomfort, diarrhea, and rectal bleeding associated with inflammatory bowel disease. The composition also includes excipients that support tablet stability and delayed release.

How to use?

Asacol tablets are taken by mouth with water. The usual total daily dose for adults is commonly in the 800 mg to 2.4 g per day range, divided across the day, with higher doses used in some situations based on disease activity and specialist direction. For maintenance, doctors often aim for the lowest dose that keeps remission stable, then adjust if symptoms start to creep back.

Swallow tablets whole. Do not crush or chew.
This matters because the coating is part of the delivery system, and breaking it can shift where the drug releases and can worsen stomach upset.

A practical routine many patients stick with:

• Take doses at consistent times each day.
• Use a phone reminder for midday doses if you work outdoors or drive long shifts.
• If nausea appears, taking with food can help some people, even though the key goal is consistent daily exposure in the bowel.

If you miss a dose, take it when you remember on the same day. If it’s close to the next scheduled dose, skip the missed one and continue as normal.

How does it work?

Mesalazine (mesalamine, 5ASA) works at the intestinal mucosa where ulcerative colitis inflammation lives. Think of it as calming the “chemical noise” that keeps the bowel lining irritated, so the surface can recover and bleeding and urgency reduce over time. Because the effect is local, many people tolerate it better than systemic anti-inflammatory drugs.

Key pharmacology points that matter in day‑to‑day use:

• Mesalazine reduces production of inflammatory mediators such as prostaglandins and can inhibit leukotriene synthesis in inflamed tissue.
• It also shows antioxidant activity, helping limit free‑radical related tissue injury in the colon.
• The tablet is designed to deliver the active drug to the bowel, where it can work where it is needed most.

Indications

Asacol is used to reduce active inflammation in ulcerative colitis and to help prevent relapses once symptoms settle. It is a cornerstone 5‑ASA option for mild-to-moderate ulcerative colitis.

Comparison

Asacol (mesalazine) sits in a stepwise ulcerative colitis plan alongside other anti-inflammatory and immune‑modifying options. The choice depends on disease extent, severity, and prior response, not on brand preference.

Mesalazine products (including Asacol and Pentasa) share the same core active ingredient (5‑aminosalicylic acid), yet they can differ in where and how the drug releases in the gut. Sulfasalazine can be effective, but in community practice I see more treatment stops due to nausea, headache, and rash; it’s a trade‑off between cost, tolerance, and individual response.

Contraindications

• Known allergy to mesalazine/mesalamine (5‑ASA) or other 5‑ASA salicylates
• Severe renal impairment
• Severe hepatic impairment
• Active stomach or duodenal ulcer disease
• Significant blood clotting disorders or unsafe bleeding tendency

Not recommended for

Asacol is not a good choice if you have a known 5‑ASA allergy, serious kidney or liver problems, active stomach or duodenal ulcers, or a bleeding problem your clinician is already worried about. It also needs individual medical advice in pregnancy and breastfeeding, especially if your ulcerative colitis is hard to keep controlled.

Side effects

More common side effects reported with oral mesalazine include:

• Nausea, abdominal discomfort, diarrhoea or looser stools
• Headache or dizziness
• Skin rash or itch
• Tiredness

Rare but serious reactions need fast attention. Mesalamine-induced acute intolerance syndrome can look like a sudden flare: cramping, diarrhoea, fever, headache, and worsening blood in stool soon after starting or increasing the dose. Hypersensitivity in people allergic to 5‑ASA (or salicylates) can also present with rash, wheeze, or facial swelling. Kidney effects are uncommon, yet clinically important because they can develop quietly, which is why prescribers often arrange baseline and periodic kidney tests for long‑term users.

One more real‑world detail: dark urine plus new flank pain during treatment is never something to “wait out,” since dehydration and kidney irritation can overlap.

Common mistakes

Small errors can lead to big frustration, even when the medicine itself is a good match.

Common patterns that delay improvement:

• Stopping early when stools look normal, then relapsing.
• Crushing or chewing tablets to “make it work faster,” which can increase upper‑GI irritation and reduce targeted delivery.
• Taking doses irregularly, then blaming the drug for “not working.”
• Ignoring dehydration during a flare; diarrhoea plus heat exposure in the UAE can worsen fatigue and headaches.
• Starting new NSAID painkillers for back or knee pain during a flare; some people find NSAIDs aggravate colitis symptoms.

Doctor opinions

Gastroenterologists tend to value mesalazine because it treats the lining directly and can reduce the need for steroids in mild-to-moderate UC. In real prescribing patterns, doctors often use it as a foundation therapy, then escalate to corticosteroids, immunomodulators, or biologics if inflammation is more aggressive or extensive. EMA guidance considers mesalazine a standard anti-inflammatory option in ulcerative colitis management pathways ^[3].

Adherence is the make‑or‑break factor I see most. People often stop once bleeding settles, then relapse weeks later and assume the medicine “failed.” UC maintenance is less emotionally rewarding than flare treatment, but it prevents the next flare. Dose simplification also matters; a prospective multicentre randomised study indexed in PubMed reported that once‑daily regimens can improve satisfaction and adherence compared with divided dosing in maintenance settings ^[4].

Frequently asked questions

Asacol onset of action

Symptom relief can begin within 1–3 weeks, yet full benefit for a flare may take longer depending on how extensive the inflammation is. Bleeding and urgency often lag behind pain improvement, so judging too early can be misleading. Clinical guidance from the European Crohn’s and Colitis Organisation frames oral 5‑ASA as a first-line therapy for mild-to-moderate UC, with response assessed over weeks rather than days. Many gastroenterologists review progress and stool markers during the first month.

Asacol and food

Asacol tablets are taken with water, and many people tolerate them well with meals. If nausea appears, taking the dose after food often reduces stomach upset without reducing local bowel action. Consistency is the main driver of stable bowel exposure. Practical prescribing advice from the World Health Organization for UC maintenance emphasises adherence as much as timing.

Alcohol and Asacol

Alcohol does not have a direct pharmacologic interaction with mesalazine, yet it can worsen diarrhoea, sleep, and dehydration during a flare. If you are actively symptomatic, reducing alcohol often improves day-to-day comfort. People with liver disease need individual advice since both disease and medicines can affect liver tests. EMA-reviewed mesalazine product information focuses on monitoring in at-risk patients rather than absolute alcohol bans.

Asacol in pregnancy and breastfeeding

Mesalazine is widely used in inflammatory bowel disease care, including during pregnancy when the benefit of controlling ulcerative colitis outweighs potential risks. The main practical point is planning: disease control before conception and avoiding flares during pregnancy are major goals in gastroenterology practice. EMA product information for mesalazine supports case-by-case use with clinical monitoring in pregnancy and lactation. Breastfed infants are also observed for diarrhoea or irritability if maternal doses are high.

Long-term kidney safety with Asacol

Kidney effects are uncommon, yet clinicians take them seriously because they can develop silently. Baseline kidney function testing and periodic follow‑up is a common plan for anyone on long-term 5‑ASA therapy. If you develop reduced urine output, flank pain, or unexplained swelling, your prescriber will want prompt assessment. Monitoring recommendations are consistent across major regulatory references for mesalazine.

Symptoms that worsen after starting

A sudden worsening soon after starting can be either an ulcerative colitis flare progression or mesalamine-induced acute intolerance syndrome. The intolerance pattern often includes fever, headache, cramping, and rapid symptom escalation soon after initiation or dose increase. This situation calls for fast contact with the treating clinician because management can include stopping mesalazine and choosing an alternative approach. PubMed-indexed gastroenterology reviews describe this intolerance syndrome as rare but clinically distinctive.

Do you offer anonymous delivery?

Front view

Side view

Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.